AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 32 min read$GMAB

Genmab A/S (GMAB) Rina-S Phase 2 Shows 45.9% ORR, 12.1-Month mDOR

Genmab reported Phase 2 results for Rina-S in platinum-resistant ovarian cancer, showing 45.9% ORR and 12.1-month mDOR in 109 patients. The treatment demonstrated activity regardless of FRα expression or prior mirvetuximab use, with mPFS of 9.5 months.

Original reporting
tradingview.com
Published Oct 3, 2026, 7:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 3, 2026, 7:44 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Genmab A/S (GMAB) Rina-S Phase 2 Shows 45.9% ORR, 12.1-Month mDOR — source image
Source · tradingview.com
Decision brief

The 30-second read

$GMABBullishMed
01

Why it matters

The disclosed ORR and mDOR metrics are strong for this patient population, positioning Genmab for a potential Phase 3 trial and future partnership or licensing opportunities.

02

Market read

First‑time positive efficacy data for a late‑stage oncology asset; likely to move Genmab's stock and influence sector sentiment.

03

What to watch

Potential competition from other FRα‑targeted agents and the need for regulatory approval timelines.

Relevance 8/10Novelty 8/10Timing: today

Background

Genmab released a BusinessWire press release reporting the Phase 2 efficacy update for its antibody‑drug conjugate Rina‑S in ovarian cancer.

Company-level read

Ticker impact

$GMABBullishHigh confidence
Context

Genmab disclosed Phase 2 data for Rina‑S showing 45.9% ORR and 12.1‑month mDOR in platinum‑resistant ovarian cancer patients.

Expected impact

likely upward pressure as investors price in the encouraging efficacy results

Evidence & confidence

The data are a first‑time disclosure of substantial efficacy metrics, a material catalyst for a biotech with a US listing.

Market effects

Sector

Strengthens the ovarian‑cancer therapeutic segment and may boost related biotech peers.

Regional

European biotech markets could see modest gains on the news.

Global

Limited to biotech investors; no broad market effect.

Counterpoint

What could challenge this read

If the data do not translate into Phase 3 success, the short‑term rally could be short‑lived.

Key entities

  • company
    Genmab A/S

    Danish biotech firm developing antibody‑drug conjugates.

  • product
    Rina‑S

    Antibody‑drug conjugate targeting FRα in ovarian cancer.

Read at source← All news

Related articles

OCT 3
$GMABMedAI 9/10

Genmab A/S: Genmab Announces Rinatabart Sesutecan (Rina-S) Phase 2 RAINFOL-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer

Genmab A/S (Nasdaq: GMAB) announced Phase 2 trial results for rinatabart sesutecan (Rina-S) in platinum-resistant ovarian cancer. The treatment showed a 45.9% objective response rate and a median duration of response of 12.1 months. The study included 109 patients and was presented at the IGCS Congress 2026. Rina-S is being evaluated in multiple Phase 3 trials for various gynecologic cancers.

finanznachrichten.de3 min
OCT 3
$GMABMedAI 8/10

Genmab reports trial results for ovarian cancer drug candidate

Genmab (GMAB) reported Phase 1/2 trial results for rinatabart sesutecan in platinum-resistant ovarian cancer, showing a 45.9% response rate and median progression-free survival of 9.5 months. The trial involved 109 patients, with common side effects including fatigue, nausea, and anemia. The drug is being evaluated in four Phase 3 trials for various gynecologic cancers.

investing.com2 min